急性冠脉综合征患者Lp-PLA2水平和心血管事件的相关性及他汀的干预效果被引量：9

下载PDF

导出

摘要目的探讨急性冠脉综合征患者脂蛋白相关磷脂酶A2（Lp-PLA2）水平与脂蛋白（a）[Lp（a）]水平以及心血管事件的相关性,并观察他汀治疗急性冠脉综合征对Lp-PLA2的影响。方法入选140例急性冠脉综合征患者,ELISA检测血浆Lp-PLA2水平和Lp（a）水平,观察两者之间的相关性。所有患者给予阿托伐他汀20 mg/d治疗,并依据Lp-PLA2水平高低分为两组,随访6个月,观察两组心血管事件的发生及Lp-PLA2水平的变化。结果 Lp-PLA2水平与Lp（a）水平无明显相关而与LDL-C、Apo B100呈正相关。他汀治疗6个月后,两组Lp-PLA2水平均较前有所降低,高Lp-PLA2水平组心血管事件发生率高于低Lp-PLA2水平组。进一步进行多元回归分析,校正其他危险因素后,LP-PLA2≥260 pg/mL的OR值仍为3.537,95%可信区间为1.222-10.237。结论急性冠脉综合征患者较高的Lp-PLA2水平预示着更高的心血管事件发生率,提示Lp-PLA2可作为心血管风险的标志物。他汀治疗可降低Lp-PLA2水平。

作者卢剑华谭健锋胡允兆郭文飞李军

机构地区广东省佛山市顺德第一人民医院高级诊疗区

出处《广东医学》 CAS 北大核心 2016年第16期2428-2430,共3页 Guangdong Medical Journal

基金广东省佛山市医学类科技攻关项目(编号:201108190) 广东省佛山市顺德区社会发展及专业镇转型升级项目(编号:顺经发[2011]206号-12)

关键词他汀 LP-PLA2 Lp(a) 急性冠脉综合征心血管事件

分类号 R562.2 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献13

1Papathanasiou AI, Pappas KD, Korantzopoulos P, et al. An epi- demiologic study of acute coronary syndromes in northwestern Greece[J]. Angiology, 2004, 55(2): 187-194.
2Nakajima T, Yamazaki K. Periodontal disease and risk of athero- sclerotic coronary heart disease [ J ]. Odontology, 2009, 97 ( 2 ) : 84 - 91.
3Spahic E, Hasic S, Kiseljakovic E, et al. Positive correlation be- tween uric acid and C -reactive protein serum level in healthy in- dividuals and patients with acute coronary syndromes [ J ]. Med Glas, 2015, 12(2) : 128 -132.
4Tang JN, Shen DL, Liu CL, et al. Plasma levels of Clq/TNF - related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris[ J]. Am J Med Sci, 2015, 349 (2) : 130 - 136.
5Charniot JC, Khani - Bittar R, Albertini JP, et al. Interpretation of lipoprotein - associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments[ J]. Int J Cardiol, 2013, 168 ( 1 ) : 132 - 138.
6Cai A, Zheng D, Qiu R, et al. Lipoprotein - associated phospho- lipase A2 ( Lp - PLA ( 2 ) ) : a novel and promising biomarker for cardiovascular risks assessment [ J ]. Dis Markers, 2013, 34 (5) : 323 - 331.
7Vittos O, Toana B, Vittos A, et al. Lipoprotein - associated phos- pholipase A2 ( Lp - PLA2) : a review of its role and significance as a cardiovascular biomarker[ J]. Biomarkers, 2012, 17 (4): 289 - 302.
8Lee JH, Engler MM. Lipoprotein - associated phospholipase A (2) : a promising vascular - specific marker for screening cardio- vascular risk? [J]. Prog Cardiovase Nurs, 2009, 24(4) : 181 - 189.
9Vickers KC, Maguire CT, Wolfert R, et al. Relationship of lipo- protein - associated phospholipase A2 and oxidized low density lip- oprotein in carotid atherosclerosis [ J ]. J Lipid Res, 2009, 50 (9) : 1735 -1743.
10Cai A, Li G, Chen J, et al. Increased serum level of Lp - PLA2 is independently associated with the severity of coronary artery disea- ses : a cross - sectional study of Chinese population[ J]. BMC Car- diovasc Disord, 2015, 15(1): 14.

二级参考文献29

1Millard RW, Tranter M. Complementary, alternative, and putative nontroponin biomarkers of acute coronary syndrome : new resources for future risk assessment calculators[ J ]. Rev Esp Cardiol (Engl Ed) , 2014,67(4) :312-320.
2Guo C, Zhang S, Zhang J, et al. Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9 [J]. Exp Ther Med, 2014,7(5) :1177-1180.
3Rubin J, Chang HJ, Nasir K, et al. Association between high-sensi- tivity C-reactive protein and coronary plaque subtypes assessed by 64- slice coronary computed tomography angiography in an asymptomatic population[J]. Circ Cardiovasc Imaging, 2011,4(3) :201-209.
4Charniot JC, Khani-Bittar R, Albertini JP, et al. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardi- ac disease, comorbidities, extension of atherosclerosis and treatments [J]. Int J Cardiol, 2013,168(1) :132-138.
5Liu J, Wang W, Qi Y, et al. Association between the lipoprotein-as- sociated phospholipase A2 activity and the progression of subclinical atherosclerosis[ J]. J Atheroscler Thromb, 2014,21 (6) :532-542.
6Ikonomidis I, Kadoglou NN, Tritakis V, et al. Association of Lp- PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease [ J]. Atherosclerosis, 2014,234( 1 ): 34-41.
7Dohi T, Miyauchi K, Ohkawa R, et al. Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography[ J]. Ann Clin Biochem, 2012, 49(Pt 6) : 527-533.
8Mani V, Woodward M, Samber D, et al. Predictors of change in ca- rotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study[ J]. Int J Cardiovasc Imaging, 2014,30(3) :571-582.
9Garcia-Salas JM, Tello-Montoliu A, Manzano-Fernandez S, et al. In- terleukin-6 as a predictor of cardiovascular events in troponin-negative non-ST elevation acute coronary syndrome patients [ J ]. Int J Clin Pract, 2014, 68 (3) :294-303.
10Okazaki S, Sakaguchi M, Miwa K, et al. Association of interleukin- 6 with the progression of carotid atherosclerosis: a 9-year follow-up study [ J ]. Stroke, 2014,45 (10) :2924-2929.